{"id":"NCT02988882","sponsor":"Ocular Therapeutix, Inc.","briefTitle":"OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis","officialTitle":"A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CACÂ®)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2016-04-27","completion":"2016-04-27","firstPosted":"2016-12-09","resultsPosted":"2018-04-30","lastUpdate":"2020-10-12"},"enrollment":86,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"OTHER","name":"Placebo Vehicle","otherNames":[]}],"arms":[{"label":"OTX-DP","type":"EXPERIMENTAL"},{"label":"PV","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis","primaryOutcome":{"measure":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6","timeFrame":"3 minutes","effectByArm":[{"arm":"OTX-DP","deltaMin":2.04,"sd":1.088},{"arm":"Placebo Vehicle","deltaMin":2.31,"sd":1.115}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Adverse Events"]}}